David John Lewis
A5102904672- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Monoclonal and Polyclonal Antibodies Research
- CNS Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Protein Degradation and Inhibitors
- Advanced Breast Cancer Therapies
- Cancer Immunotherapy and Biomarkers
- Biosimilars and Bioanalytical Methods
- Acute Lymphoblastic Leukemia research
- Gastrointestinal Tumor Research and Treatment
- Cancer Treatment and Pharmacology
- Biochemical and Molecular Research
- HIV/AIDS drug development and treatment
- Chromatin Remodeling and Cancer
- HER2/EGFR in Cancer Research
- T-cell and Retrovirus Studies
- Glioma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Vascular Tumors and Angiosarcomas
- Cutaneous lymphoproliferative disorders research
- Autoimmune and Inflammatory Disorders Research
- Corneal Surgery and Treatments
University Hospitals Plymouth NHS Trust
2018-2025
Derriford Hospital
2017-2025
Plymouth Hospital
2018-2025
Lund University
2022
Repatriation General Hospital
2022
Skåne University Hospital
2022
Royal Adelaide Hospital
2022
University of Plymouth
2020-2021
Heart of England NHS Foundation Trust
2015
University of Surrey
2015
PURPOSE Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20 + B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation across B-cell non-Hodgkin lymphoma subtypes. PATIENTS AND METHODS In the dose-expansion cohort of phase I/II study (ClinicalTrials.gov identifier: NCT03625037 ), adults with relapsed or refractory large and at least two prior...
Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab followed by maintenance therapy older patients untreated mantle-cell lymphoma.
Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent (cBTKi) pretreated mantle-cell lymphoma (MCL), population poor prognosis.Patients cBTKi relapsed/refractory (R/R) MCL received monotherapy multicenter phase I/II trial (BRUIN; ClinicalTrials.gov identifier: NCT03740529). Efficacy was assessed first 90 consecutively enrolled who met criteria for inclusion primary...
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Gemcitabine + oxaliplatin (GemOx) rituximab, a standard salvage therapy, yields complete response (CR) rates of approximately 30% and median overall survival (OS) 10-13 months. disease fare worse, CR rate 7% for subsequent therapies OS 6 Epcoritamab, CD3xCD20 bispecific antibody approved the treatment R/R DLBCL after ≥2 therapy lines, has shown promising safety efficacy in various...
Summary Ibrutinib is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and clinical trial data supports use at second line compared to later relapse. We aimed investigate outcomes tolerability ibrutinib when given in a real‐world setting. Our multicentre retrospective analysis included 211 R/R MCL patients, median age 73 years, receiving second‐line within the United Kingdom’s National Health Service. Overall response was 69% (complete 27%). The...
Introduction: Classical Hodgkin Lymphoma (cHL) is frequently accompanied by the 9p24.1 amplicon, which contains PD-L1 and PD-L2 immune checkpoint genes results in their overexpression. Blockade of PD-1/PD-L1 PD-1/PD-L2 interactions with anti–PD-1 antibodies clinically effective; however, it has not been established if blockade interaction alone sufficient for therapeutic effect. Avelumab a fully human IgG1 monoclonal antibody that selectively binds to PD-L1, leaving intact, thus enabling...
Abstract The 9p24.1 chromosomal alteration in classical Hodgkin lymphoma (cHL) is associated with increased expression of programmed death ligand 1 (PD-L1)/PD-L2 and an immunosuppressive tumor microenvironment. Blockade PD-L1/PD-1 interactions avelumab (anti–PD-L1) hypothesized to restore antitumor immunity. JAVELIN Hodgkins was a phase 1b, multiple-dose, open-label, randomized, parallel-arm trial patients relapsed/refractory (R/R) cHL. Primary end points included target occupancy by...
Abstract Time to progression of disease (POD) after first-line (1L) therapy is prognostic in mantle cell lymphoma (MCL), although studies have included a broad range 1L, second-line (2L), and subsequent lines therapy. The purpose this study was evaluate the factors predicting outcomes patients with relapsed/refractory (R/R) MCL exclusively initiating 2L Bruton’s tyrosine kinase inhibitors (BTKis) 1L rituximab-containing Patients were accrued from 8 international centers (7 main, 1 validation...
7525 Background: Outcomes are poor for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Effective treatments (tx) that drive deep, durable responses and long-term benefit needed. In the pivotal EPCORE NHL-1 trial (NCT03625037), single-agent epcoritamab (epcor) showed high complete response (CR) MRD-negativity rates, a median duration of (mDoR) not reached (NR) in pts who achieved CR, manageable safety profile as an off-the-shelf, subcutaneous (SC), CD3xCD20...
Summary The optimal therapeutic approach for relapsed/refractory (R/R) Waldenström's Macroglobulinaemia (WM) has not been clearly defined, especially after treatment with chemoimmunotherapy (CIT) and covalent Bruton's tyrosine kinase inhibitors (cBTKi). PembroWM trial is a multi‐centre, phase II, single‐arm study assessing the safety, tolerability efficacy of rituximab pembrolizumab in R/R WM patients who had received at least one prior line treatment, all having relapsed post‐CIT most also...
Abstract During the COVID-19 pandemic, ibrutinib with or without rituximab was approved in England for initial treatment of mantle cell lymphoma (MCL) instead immunochemotherapy. Because limited data are available this setting, we conducted an observational cohort study evaluating safety and efficacy. Adults receiving untreated MCL were evaluated toxicity, response, survival, including outcomes high-risk (TP53 mutation/deletion/p53 overexpression, blastoid/pleomorphic, Ki67 ≥ 30%). A total...